Table 6.
Baseline and 12-month follow-up cardiopulmonary parameters in study population stratified by ARNI dose.
| ARNI1 | ARNI2 | ARNI3 | ||||
|---|---|---|---|---|---|---|
| Baseline (n = 90) | 12-Month Follow-Up (n = 39) | Baseline (n = 40) | 12-Month Follow-Up (n = 48) | Baseline (n = 2) | 12-Month Follow-Up (n = 47) | |
| VO2peak (mL/kg/min) | 15.3 ± 3.7 | 16.5 ± 4.2 | 14.8 ± 3.6 | 17.5 ± 4.7 ** | 14.2 ± 2.7 | 18.9 ± 4.7 |
| Predicted VO2peak (%) | 56.4 ± 13.9 | 62.5 ± 14.4 * | 54.0 ± 14.5 | 65.4 ± 16.0 ** | 50.5 ± 21.9 | 68.7 ± 19.1 |
| Watt Max (W) | 72.8 ± 25.1 | 80.6 ± 31.6 | 78.2 ± 24.9 | 86.8 ± 28.9 | 63.0 ± 7.0 | 102.8 ± 30.7 |
| VE/VCO2slope | 33.4 ± 6.2 | 32.2 ± 5.9 | 32.3 ± 5.6 | 31.3 ± 7.1 | 38.1 ± 3.8 | 28.9 ± 5.2 ** |
| RER | 1.14 ± 0.12 | 1.13 ± 0.09 | 1.13 ± 0.07 | 1.16 ± 0.11 | 1.07 ± 0.10 | 1.15 ± 0.10 |
| HR Rest (bpm) | 72.4 ± 10.8 | 68.7 ± 7.2 | 70.9 ± 10.9 | 68.3 ± 9.1 | 80.5 ± 27.6 | 69.4 ± 10.1 |
| HR Peak (bpm) | 106.6 ± 18.2 | 106.7 ± 19.9 | 106.3 ± 19.3 | 110.3 ± 15.9 | 126.0 ± 26.9 | 115.1 ± 22.1 |
| HRR (bpm) | 11.4 ± 9.5 | 14.1 ± 10.9 | 12.2 ± 11.2 | 15.0 ± 9.9 | 23.0 ± 2.8 | 18.7 ± 10.0 |
| AT-VO2 (mL/kg/min) | 11.4 ± 2.9 | 12.3 ± 2.9 | 11.4 ± 2.3 | 12.2 ± 3.7 | 10.9 ± 2.7 | 13.0 ± 2.9 |
| AT-VO2 (%) | 40.9 ± 11.5 | 45.7 ± 13.5 | 46.0 ± 13.4 | 45.8 ± 13.4 | 41.0 ± 11.3 | 50.2 ± 12.5 ** |
| AT-Watt (W) | 56.1 ± 24.8 | 57.2 ± 25.6 | 59.5 ± 19.7 | 55.1 ± 19.2 | 48.0 ± 21.3 | 67.3 ± 22.9 ** |
| O2-Pulse (mL/beat) | 11.4 ± 3.0 | 12.2 ± 3.5 | 12.6 ± 3.2 | 13.2 ± 3.8 | 10.2 ± 2.4 | 14.4 ± 3.8 * |
| ΔVO2/Δwork (mL/min/watt) | 9.2 ± 1.6 | 9.6 ± 1.8 | 9.0 ± 1.7 | 10.1 ± 1.5 ** | 9.5 ± 0.6 | 10.1 ± 1.5 |
| Peak Ventilation (L/min) | 45.8 ± 10.6 | 55.0 ± 17.9 ** | 52.7 ± 14.7 | 56.4 ± 15.0 | 47.2 ± 9.5 | 63.6 ± 18.8 ** |
| TIDAL volume (mL/kg) | 1.5 ± 0.38 | 1.7 ± 0.56 * | 1.7 ± 0.47 | 1.6 ± 0.44 | 1.6 ± 0.17 | 1.9 ± 0.5 |
| Respiratory Rate (breaths/min) | 30.8 ± 6.3 | 33.2 ± 6.9 | 31.7 ± 6.5 | 34.7 ± 6.0 * | 30.0 ± 2.8 | 32.9 ± 7.0 ** |
Captions: * p < 0.05, ** p < 0.001 vs. baseline; ARNI1: angiotensin receptor neprilysin inhibitor (ARNI) dose of 24/26 mg bid; ARNI2: ARNI dose of 49/51 mg bid; ARNI3: ARNI dose of 97/103 mg bid; AT: anaerobic threshold; RER: respiratory exchange ratio; VE: ventilation; VE/VCO2slope: the slope of increase in ventilation over carbon dioxide output; VO2: oxygen consumption; HR: heart rate; HRR: heart rate recovery.